Terkeltaub, Robert http://orcid.org/0000-0001-5368-7473
Funding for this research was provided by:
VA (I01 BX001660-06)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR060772)
Article History
Accepted: 4 September 2023
First Online: 11 October 2023
Declarations
:
: Research conducted by Robert Terkeltaub was funded by the VA Research Service (I01 BX001660-06) and National Institutes of Health (AR060772).
: Robert Terkeltaub has recently served, or currently serves, as a consultant for Allena, LG Chem, Fortress/Urica, Selecta Biosciences, Horizon Therapeutics, Atom Bioscience, Acquist Therapeutics, Generate Biomedicines, Astra-Zeneca, and Synlogic, and was a previous recipient of a research grant from AstraZeneca. He serves as the non-salaried President of the G-CAN (Gout, Hyperuricemia, and Crystal-Associated Disease Network) research society, which annually receives unrestricted arms-length grant support from pharma donors.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.